Adma Biologics reported $121.98M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Adma Biologics USD 121.98M 4.43M Jun/2025
Alnylam Pharmaceuticals USD 773.69M 179.5M Jun/2025
Dynavax Technologies USD 95.44M 30.44M Jun/2025
Takeda JPY 1.11T 60B Jun/2025